Latest news
Ten Years of MS Data Make Delay Harder to Defend
A decade of OPERA follow-up shows durable relapse and disability control with ocrelizumab, while patients who started high-efficacy therapy later never fully caught up. The escalation debate now carries a long-term cost.
Novo’s €1.165B Bet Targets the Burden of Weekly Injections
Survival Is No Longer Enough: Mental Health Moves Into Congenital Heart Care
The App Wasn’t Enough: Nurse-Led Digital Diabetes Care Linked to Better HbA1c and Adherence
Small-Cell Lung Cancer May Be Done Irradiating Healthy Brains
IPM Brief – Issue 32 | BURN AFTER READING
Erectile Dysfunction Is Already a Cardiovascular Risk Marker. New Data Link It to Glaucoma Too
Retatrutide Isn’t Approved. Online, ‘Reta’ Is Already a Weight-Loss Brand
Pembrolizumab Just Lost a Head-to-Head Survival Fight
SMA Treatment Finally Reaches the Muscle
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.